Evidence map›Paper›PMID 24069438›Full record

ArticlePloS one2013

Disruption of the endothelial barrier by proteases from the bacterial pathogen Pseudomonas aeruginosa: implication of matrilysis and receptor cleavage.

Nathalie Beaufort, Elisabeth Corvazier, Saouda Mlanaoindrou, Sophie de Bentzmann, Dominique Pidard

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. A Secreted Glutamate-Specific Serine Protease fromPathogens (Basel, Switzerland) · 2026
    Article
  3. Exploring the Role ofACS infectious diseases · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Adsorption of extracellular proteases and pyocyanin produced byCurrent research in microbial sciences · 2022
    Article
  10. Molecular Mechanisms Involved in Pseudomonas aeruginosa Bacteremia.Advances in experimental medicine and biology · 2022
    Review
  11. The Role ofToxins · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. Frontiers in immunology · 2020
    Article
  16. Article
  17. Article
  18. DisarmingFrontiers in microbiology · 2019
    Article
  19. Thorax · 2018
    Article
  20. Frontiers in immunology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Nathalie BeaufortInserm, U698, Paris, France ; Université Denis Diderot, UMR-S698, Paris, France.
Elisabeth Corvazier
Saouda Mlanaoindrou
Sophie de Bentzmann
Dominique Pidard
Délégation Paris 7 · FRAix-Marseille Université · FRInserm · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Within the vasculature, uncontrolled pericellular proteolysis can lead to disruption of cell-to-cell and cell-to-matrix interactions and subsequent detachment-induced cell apoptosis, or anoikis, contributing to inflammatory vascular diseases, with the endothelium as the major target. Most studies so far have focused on endogenous proteinases. However, during bloodstream infections, bacterial proteinases may also trigger endothelial anoikis. We thus investigated the potential apoptotic activity of the proteinases secreted by the haematotropic opportunistic pathogen, Pseudomonas aeruginosa, and particularly its predominant metalloproteinase, LasB. For this, we used the secretome of the LasB-expressing pseudomonal strain, PAO1, and compared it with that from the isogenic, LasB-deficient strain (PAO1∆lasB), as well as with purified LasB. Secretomes were tested for apoptotic activity on cultured human endothelial cells derived from the umbilical vein or from the cerebral microvasculature. We found that the PAO1 secretome readily induced endothelial cell anoikis, as did secretomes of LasB-positive clinical pseudomonal isolates, while the PAO1∆lasB secretome had only a limited impact on endothelial adherence and viability. Notably, purified LasB reproduced most of the effects of the LasB-containing secretomes, and these were drastically reduced in the presence of the LasB-selective inhibitor, phosphoramidon. A precocious and extensive LasB-dependent degradation of several proteins associated with the endothelial extracellular matrix, fibronectin and von Willebrand factor, was observed by immunofluorescence and/or immunoblotting analysis of cell cultures. Moreover, the PAO1 secretome, but not that from PAO1∆lasB, specifically induced rapid endoproteolysis of two major interendothelial junction components, VE-cadherin and occludin, as well as of the anti-anoikis, integrin-associated urokinase receptor, uPAR. Taken as a prototype for exogenous haemorrhagic proteinases, pseudomonal LasB thus appears to induce endothelial anoikis not only via matrilysis, as observed for many pro-apoptotic proteinases, but also via cleavage of some essential cell-to-cell and cell-to-matrix adhesion receptors implicated in the maintenance of the endothelial barrier.

Indexed as

Bacterial ProteinsCell AdhesionCell DeathCell LineCell SurvivalEndothelial CellsEndothelium, VascularExtracellular MatrixHumansMembrane Transport ProteinsMetalloendopeptidasesPeptide HydrolasesProteolysisPseudomonas aeruginosaPseudomonas InfectionsReceptors, Urokinase Plasminogen ActivatorBacterial ProteinsMembrane Transport ProteinsMetalloendopeptidasesPeptide Hydrolasespseudolysin, Pseudomonas aeruginosaReceptors, Urokinase Plasminogen Activator

Identifiers

PMID24069438
PMCPMC3777978
OpenAlexW2057288160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.